GET DAILY SIGNALSIntuitive Surgical (ISRG) Delivers +19% Revenue Growth in Q2 2026
Key Takeaways
- Q2 2026 revenue reached $2.89 billion, up 19% year over year and above consensus estimates.
- Non-GAAP diluted EPS of $2.80 beat analyst expectations by approximately $0.32 to $0.39.
- Worldwide da Vinci and Ion procedures grew about 16% year over year.
- 468 da Vinci systems placed, including 246 da Vinci 5 systems, expanding the installed base to 11,710.
- Full-year 2026 guidance reaffirmed with da Vinci procedure growth expected at 13.5% to 15.5%.
- GAAP net income rose to $818 million, or $2.29 per diluted share.
Earnings Context and Why It Matters
Intuitive Surgical’s quarterly results provide key insights into demand for its robotic-assisted surgical systems and related instruments. Strong procedure volume growth signals continued adoption of minimally invasive techniques across hospitals worldwide. The report also highlights system placements, leasing trends, and margin performance, which influence investor views on the company’s long-term growth trajectory in the medical device sector.
Reported Results
Intuitive Surgical reported second-quarter 2026 revenue of $2.89 billion, a 19% increase from $2.44 billion in the same quarter of 2025. Instruments and accessories revenue rose 18% to $1.73 billion, while systems revenue increased to $685 million. Non-GAAP net income attributable to the company reached $1.00 billion, or $2.80 per diluted share, compared with $0.80 billion, or $2.19 per diluted share, a year earlier. GAAP net income was $818 million, or $2.29 per diluted share. Both revenue and non-GAAP EPS exceeded consensus estimates. Worldwide procedures grew approximately 16%, with da Vinci procedures up about 15% and Ion procedures up 36%. The company placed 468 da Vinci systems and 55 Ion systems during the quarter. I also checked this using Tickeron’s AI Screener to see how ISRG compares to others in the industry.
Market Reaction and Investor Sentiment
Shares of ISRG typically move on earnings beats driven by procedure growth and system placements. The strong Q2 results, including revenue and earnings outperformance, reinforced positive sentiment heading into the report. Investors focused on the company’s ability to sustain momentum amid broader healthcare spending trends and adoption of robotic surgery.
Forward Outlook and Key Factors to Monitor
Intuitive Surgical reaffirmed its 2026 full-year outlook, expecting worldwide da Vinci procedure growth of 13.5% to 15.5%. Non-GAAP gross profit margin is projected in the 68.0% to 69.0% range, incorporating an estimated 1.0% impact from tariffs. Non-GAAP operating expense growth is anticipated between 11% and 13%.
Investors will watch procedure volume trends, system placement rates, and the mix between capital sales and leasing arrangements. The expanding installed base of da Vinci and Ion systems supports recurring revenue from instruments and accessories. Tariff developments and their effect on margins remain a key variable through year-end. Upcoming catalysts include updates on digital solutions and new system adoption rates. From what I see, these factors will be important to track closely in the coming quarters.
How Tickeron’s AI Screener Fits Into My Research
As part of my regular analysis process, I turn to Tickeron’s AI Screener to filter stocks and ETFs by technical patterns, fundamentals, and performance metrics. This tool helps me quickly identify how a company like ISRG stacks up against peers and spot broader sector trends that might not be obvious from the earnings release alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsContributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ISRG sees MACD Histogram crosses below signal line
ISRG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 33 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 17 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 61 cases where ISRG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 57 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
Following a +5.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 210 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 183 of 264 cases where ISRG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.495) is normal, around the industry mean (4.877). P/E Ratio (49.420) is within average values for comparable stocks, (37.682). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How Do Digital Wallets Work and Are They Safe to Use?
Revolutionizing Day Trading with AI: Tickeron's Advanced Trading Bots for High Volatility Stocks
From Analysis to Action: AI Trading Bots Redefining Hedge Fund Operations
Tvardi Therapeutics Reports Robust Q1 2025 Results and Clinical Advancements
Navigating Investment Diversification: Blend or Balanced Funds?
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther
Advertisement